Market Place
Sourcing Support
AC Immune Reports Positive Interim Results in Parkinson`s Disease
14 Nov 2024 //
GLOBENEWSWIRE
AC Immune to Present at the Jefferies 2024 London Conference
13 Nov 2024 //
GLOBENEWSWIRE
AC Immune Reports Q3 2024 Financial Results & Corporate Update
05 Nov 2024 //
GLOBENEWSWIRE
AC Immune Gets Milestone Payment for ACI-35.030 Trial
17 Sep 2024 //
GLOBENEWSWIRE
AC Immune`s PI-2620 Tau-PET Diagnostic Receives Fast Track Designation
28 Aug 2024 //
GLOBENEWSWIRE
AC Immune Reports Q2 2024 Results And Corporate Update
06 Aug 2024 //
GLOBENEWSWIRE
AC Immune Claims New Alzheimer`s ADC Has `Landmark` Potential
31 Jul 2024 //
FIERCE BIOTECH
AC Immune Unveils Novel ADC Technology at AAIC 2024
31 Jul 2024 //
GLOBENEWSWIRE
AC Immune`s ACI-35.030 Gets FDA Fast Track For Alzheimer`s
25 Jul 2024 //
GLOBENEWSWIRE
AC Immune Showcases MorADC Platform At AAIC 2024
16 Jul 2024 //
GLOBENEWSWIRE
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
28 May 2024 //
GLOBENEWSWIRE
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
14 May 2024 //
BIOPHARMADIVE
AC Immune, Takeda Sign Alzheimer`s Amyloid Beta Immunotherapy Deal
13 May 2024 //
BUSINESSWIRE
AC Immune, Takeda Sign Alzheimer`s Amyloid Beta Immunotherapy Option/License
13 May 2024 //
GLOBENEWSWIRE
AC Immune Reports Q1 2024 Results, Corporate Update
13 May 2024 //
GLOBENEWSWIRE
AC Immune Reports Full Year 2023 Financial Results
14 Mar 2024 //
GLOBENEWSWIRE
AC Immune Announces Upcoming Presentations at AD/PD 2024
22 Feb 2024 //
GLOBENEWSWIRE
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
22 Jan 2024 //
GLOBENEWSWIRE
Roche’s Genentech returns Alzheimer’s assets to AC Immune
22 Jan 2024 //
FIERCE BIOTECH
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline
03 Jan 2024 //
GLOBENEWSWIRE
AC Immune™s Targeted Anti-pTau Active Immunotherapy Advances into Ph 2b Trial
15 Dec 2023 //
GLOBENEWSWIRE
AC Immune Announces Pricing of Underwritten Offering of Common Shares
15 Dec 2023 //
GLOBENEWSWIRE
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO
01 Dec 2023 //
GLOBENEWSWIRE
AC Immune to Present at the Jefferies 2023 London Healthcare Conference
07 Nov 2023 //
GLOBENEWSWIRE
AC Immune Reports Third Quarter 2023 Financial Results
03 Nov 2023 //
GLOBENEWSWIRE
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging
02 Nov 2023 //
GLOBENEWSWIRE
AC Immune Data Show ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
27 Oct 2023 //
GLOBENEWSWIRE
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
17 Oct 2023 //
GLOBENEWSWIRE
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
05 Oct 2023 //
GLOBENEWSWIRE
AC Immune to Present at H.C. Wainwright 25th Annual Global Investment Conference
05 Sep 2023 //
GLOBENEWSWIRE
AC Immune Reports Q2 2023 Financial Results and Provides a Corporate Update
04 Aug 2023 //
GLOBENEWSWIRE
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
28 Jul 2023 //
GLOBENEWSWIRE
AC Immune SA Appoints New Chief Medical Officer
26 Jul 2023 //
GLOBENEWSWIRE
AC Immune Showcasing Precision Medicine Programs at AAIC 2023
03 Jul 2023 //
GLOBENEWSWIRE
AC Immune Receives FDA Fast Track Designation for ACI-24.060, to Treat Alzheimer
27 Jun 2023 //
GLOBENEWSWIRE
AC Immune Holds Annual General Meeting of Shareholders
23 Jun 2023 //
GLOBENEWSWIRE
AC Immune to Host Key Opinion Leader Webinar on Prevention of Alzheimer`s Disease
05 Apr 2023 //
GLOBENEWSWIRE
AC Immune at AD/PD 2023 to Present Data from Precision Medicine Pipeline
20 Mar 2023 //
GLOBENEWSWIRE
AC Immune to Report Full Year 2022 Financial Results
08 Mar 2023 //
GLOBENEWSWIRE
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs
07 Feb 2023 //
GLOBENEWSWIRE
AC Immune to Present at the SVB Securities Global Biopharma Conference
02 Feb 2023 //
GLOBENEWSWIRE
AC Immune reports positive data from Alzheimer’s disease vaccine trial
27 Jan 2023 //
CLINICAL TRIALS ARENA
AC Immune`s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer`s Shows Safety
26 Jan 2023 //
GLOBENEWSWIRE
Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620
18 Jan 2023 //
GLOBENEWSWIRE
AC Immune’s Alzheimer’s Disease Vaccine Selected For Further Development
01 Dec 2022 //
PRESS RELEASE
AC Immune ™ Alzheimer`s Disease Vaccine ACI-35.030 for Further Development
30 Nov 2022 //
GLOBENEWSWIRE
AC Immune to Present Progress of Alzheimer’s Disease Programs
23 Nov 2022 //
GLOBENEWSWIRE
Genentech, AC Immune reveal more about crenezumab failure
02 Aug 2022 //
FIERCEBIOTECH
AC Immune Holds Annual General Meeting Of Shareholders
24 Jun 2022 //
PRESS RELEASE
AC Immune Provides Update On Alzheimer’s Prevention Initiative Study Evaluating Crenezumab
16 Jun 2022 //
PRESS RELEASE
AC Immune, Janssen Alzheimer`s vaccine spurs tau antibodies
15 Feb 2022 //
FIERCEBIOTECH
Roche, AC Immune attempt to flesh out anti-tau Alzheimer`s data
11 Nov 2021 //
ENDPTS
AC Immune Announces Late-Breaker Presentation by Genentech at CTAD on Phase 2
10 Nov 2021 //
PRESS RELEASE
New Alzheimer’s drug slowed cognitive decline, study says
31 Aug 2021 //
STRIPES
Genentech/AC Immune’s Anti-Tau Antibody Slows Cognitive Decline
31 Aug 2021 //
SCRIP
Cautiously optimistic, AC Immune delivers a mixed set of Alzheimer`s data
31 Aug 2021 //
ENDPTS
AC Immune acquires Parkinson’s disease vaccine candidate
29 Jul 2021 //
PHARMATIMES
AC Immune Hosts Investor Webinar Highlighting the Power of its Morphomer
31 Mar 2021 //
GLOBENEWSWIRE
AC Immune Hosts Investor Webinar Highlighting the Power of its Morphomer
31 Mar 2021 //
PRESS RELEASE
AC Immune Announces New Clinical Results in Down Syndrome and Plans
16 Mar 2021 //
GLOBENEWSWIRE
